Articles By Wayne Koberstein, Executive Editor

Company To Watch: GeNeuro
Company To Watch: GeNeuro Outside skepticism about GeNeuro’s scientific concept has made fund-raising even harder than usual for a startup. But the Swiss company has found considerable support in Europe.  Continue Reading...
  • Astellas Puts Oncology Front & Center
    Astellas Puts Oncology Front & Center

    Astellas has placed a big emphasis on oncology this year, pointing to its many assets, particularly in targeted therapies that are later stage, but also focusing through partnerships on immuno-oncology (IO). A conversation with Drs. Steven Benner, head of oncology, and Peter Sandor, head of oncology marketing strategy, follows.

  • An Introvert’s View Of The Industry — Or Travels With Incredulity
    An Introvert’s View Of The Industry — Or Travels With Incredulity

    When I leave my writer’s lair and go out into the world, I feel like the tortoise in a race of hares. People move around me at the speed of light, most lost in their screens, smiling at machines.

  • IO KOLs Speak On
    IO KOLs Speak On

    More thoughts and comments from cancer immunotherapy experts augment our 2017 immuno-oncology update.

  • Our Annual Cancer Immunotherapy Update
    Our Annual Cancer Immunotherapy Update

    When we started our series, “Combination Cancer Immunotherapy — A Virtual Roundtable,” in 2014, our basic assumptions were not the consensus view. We assumed immunotherapy, now more commonly called immuno-oncology (IO), would become the dominant form of cancer treatment and central target of academic and industry research in oncology. We assumed a single, backbone therapy would become the pillar around which combinations of therapeutics with complementary targets would form. And we assumed the IO field, especially in its combination approaches, would pose profound scientific and business challenges as it took over as the central focus of oncology in general. Our assumptions turned out to be correct. Now, all IO has to do is catch up with itself.

  • Companies To Watch: Frequency Therapeutics
    Companies To Watch: Frequency Therapeutics

    Frequency Therapeutics is an early-stage developer of small molecule drugs to activate “progenitor cells” and restore healthy tissue. Its lead program is in treating hearing loss by regenerating sensory cells in the inner ear, for which it is planning a Phase 1 trial to launch in mid-2018.

  • Takeda Aims To Invent It Here & There
    Takeda Aims To Invent It Here & There

    Takeda’s chief medical and scientific officer talks about R&D, business development, and partnering.

  • Industry Explorers: Leading Business With Science — Part 2
    Industry Explorers: Leading Business With Science — Part 2

    We continue the story of Geert Cauwenbergh whose nearly 40 years in the industry included work with Paul Janssen as well as being a startup entrepreneur with RXi Pharmaceuticals.

  • Companies To Watch: Noveome Biotherapeutics
    Companies To Watch: Noveome Biotherapeutics

    To heal the wounds — maintaining and restoring cellular homeostasis with novel secretomes.

  • From Disney’s World To DC — City Hopping For ENDO & AACR
    From Disney’s World To DC — City Hopping For ENDO & AACR

    Orlando, the city of warmth and happiness by design, hosted the Endocrine Society’s annual ENDO event this year, overlapping the Washington, DC-hosted AACR, the yearly confab by the American Association for Cancer Research, by several days. I was determined to visit both shows.

  • Leading Business With Science: Geert Cauwenbergh of RXi
    Leading Business With Science: Geert Cauwenbergh of RXi

    Geert Cauwenbergh now can look back at his almost four decades in the industry — from his formative years working with Paul Janssen building a small company into a global phenomenon, to his later years as a startup entrepreneur with RXi — and reflect on how most of it has turned upon a snap decision.

  • Companies To Watch: Aridis Pharmaceuticals
    Companies To Watch: Aridis Pharmaceuticals

    An anti-infective immunotherapy developer on a mission to replace antibiotics with engineered antibodies and novel mechanisms.

  • Preventing Delayed Cerebral Ischemia (DCI): Edge Therapeutics
    Preventing Delayed Cerebral Ischemia (DCI): Edge Therapeutics

    In Phase 3 with an innovatively delivered drug to treat a deadly complication of ruptured brain aneurysm.

  • Grünenthal’s Plan To Grow Globally & Expand Its Pipeline
    Grünenthal’s Plan To Grow Globally & Expand Its Pipeline

    Board Chairman & CEO Gabriel Baertschi talks about why the private, European-based company is widening its base with new approaches and technologies for treating pain and, now, related conditions.

  • Contrasts & Creativity at BIO CEO & Investor 2017
    Contrasts & Creativity at BIO CEO & Investor 2017

    At BIO CEO many of the companies on my radar this year are in the metabolic/endocrinology area, over which diabetes has long reigned. But the area is now expanding noticeably into other spheres such as neurodegeneration and cardiovascular. As Albion Fitzgerald, chairman of CohBar, says “During the next 15 years, there will be five times as many deaths from noncommunicable diseases as from the old historic communicable diseases, and most noncommunicable diseases are metabolic diseases.”

More From Wayne Koberstein
Wayne Koberstein

Wayne Koberstein


Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.